Tradestie Institutional Equity Comparison Engine
CDT vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, CDT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CDT N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
ENTX
1Y -86.8% vs +24.7% ยท 52W Pos 2% vs 73%
Options & Structure Winner
ENTX
BREAKDOWN (N/A IV) vs CONSOLIDATION (33rd %ile IV)
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap
$571.2M
1M Return
+9.44%
1Y Return
+24.72%
Forward P/E
N/M
Unified AI Score
47.5 / 100
HOLD
Tech 52.0
Fund 49.0
Flow 72.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CDT -86.78%
ENTX +24.72%
Spread: +111.5 pp (ENTX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CDT TTM Op. Margin: 0.0%
ENTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs ENTX. Trailing 12-month operating profitability (CDT 0.0% vs ENTX 0.0%) and valuation multiples (CDT N/M vs ENTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CDT | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $507,528 | $571.2M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | CDT |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -69.7% | -20.3% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 2% ($0โ$11) | 73% ($1โ$4) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | -17.75ฮฒ ยท 10175% Vol | 0.92ฮฒ ยท 53% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 31.6 / 100 (SELL) | 47.5 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CDT vs ENTX Buy Guide
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ENTX
CONSOLIDATION
83d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
33rd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CDT nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.